Antisense oligonucleotides in the treatment of bladder cancer

Bibliography

• GREEN FL, PAGE DL, FLEMING ID et al.: AJCC Cancer Staging Handbook. 6th Edition. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M (Eds), Springer, NY, USA (2002).
   Google Scholar
• DE BRAUD F, MAFFEZZINI M, VITALE Vet al.: Bladder cancer. Crit. Rev. Oncol Hematol (2002) 41(1):89–106.
   Google Scholar
• SCHENKMAN E, LAMM DL: Superficial bladder cancer therapy. ScienvficWorldJournal (2004) 4\(Suppl. 1):387–399.
   Google Scholar
• HENEY NM, AHMED S, FLANNAGAN MJ et al.: Superficial bladder cancer: progression and recurrence. J. Urol. (1983) 130:1083–1086.
   PubMed Web of Science ®Google Scholar
• ABEL PD, HALL RR, WILLIAMS G: Should pT1 transitional cell carcinomas of the bladder still be classified as superficial? Br. J. Urol. (1988) 62:235–239.
   Web of Science ®Google Scholar
• OOSTERLINCK W, KURTH KH, SCHRODER F, BULTINCK J, HAMMOND B, SYLVESTER R: A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, Ti papillary carcinoma of the bladder. J. Urol. (1993) 149(4):749–752.
   PubMed Web of Science ®Google Scholar
• TOLLEY DA, PARMAR MK, GRIGOR KM et al.: The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J. Urol. (1996) 155(4):1233–1238.
   PubMed Web of Science ®Google Scholar
• SYLVESTER RJ, OOSTERLINCK W, VAN DER MEIJDEN AP: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta Ti bladder cancer: a meta-analysis of published results of randomized clinical trials. J. Urol. (2004) 171(6 Pt 1):2186–2190.
   Google Scholar
• OOSTERLINCK W, LOBEL B, JAKSE G, MALMSTROM PU, STOCKLE M, STERNBERG C: Guidelines on bladder cancer. Eur. Urol. (2002) 41(2):105–112.
   PubMed Web of Science ®Google Scholar
• JAKSE G, HALL R, BONO A et ell.: Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group Phase II protocol 30861. Eur. Urol. (2001) 40(2):144–150.
   Google Scholar
• KAMAT AM, LAMM DL: Immunotherapy for bladder cancer. Curr. Urol. Rep. (2001) 2(1):62–69.
   PubMedGoogle Scholar
• BASSI P: BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer. Surg. Oncol. (2002) 11(1-2):77–83.
   PubMed Web of Science ®Google Scholar
• LAMM DL: BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology (Huntingt.) (1995) 9(10):947–952.
   PubMedGoogle Scholar
• KAMAT AM, LAMM DL: Intravesical therapy for bladder cancer. Urology (2000) 55(2):161–168.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-PINEIRO JA, MARTINEZ-PINEIRO L: BCG update: intravesical therapy. [Review]. Eur. Urol. (1997) 31\(Suppl. 1):31–41.
   Google Scholar
• WITJES JA, VAN DER MEIJDEN AP, WITJES WP, DOESBURG W, SCHAAFSMA HE, DEBRUYNE FM: A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. Eur. Cancer (1993) 29A(12):1672–1676.
   Google Scholar
• LAMM DL, BLUMENSTEIN BA, CRAWFORD ED et al.: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J. Med. (1991) 325(17):1205–1209.
   PubMed Web of Science ®Google Scholar
• PAGANO F, BASSI P, MILANI C, MENEGHINI k MARUZZI D, GARBEGLIO k A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? Urol. (1991) 146(1):32–35.
   Google Scholar
• MELEKOS MD, ZARAKOVITIS IE, FOKAEFS ED et al.: Intravesical bacillus Calmette-Guerin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumours. Oncology (Huntingt.) (1996) 53(4):281–288.
   Google Scholar
• DE JAGER R, GUINAN P, LAMM D et al.: Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six Phase II clinical trials. Urology (1991) 38(6):507–513.
   Google Scholar
• SMITH JA JR, CRAWFORD ED, PARADELO JC et al.: Treatment of advanced bladder cancer with combined preoperative irradiation and radical cystectomy versus radical cystectomy alone: a Phase III intergroup study./ Urol. (1997) 157(3):805–807.
   PubMed Web of Science ®Google Scholar
• COPPIN CM, GOSPODAROWICZ MK, JAMES K et al.: Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol (1996) 14(11):2901–2907.
   PubMed Web of Science ®Google Scholar
• SHIPLEY WU, KAUFMAN DS, TESTER WJ, PILEPICH MV, SANDLER HM: Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer (2003) 97(8 Suppl.):2115–2119.
   Google Scholar
• STERNBERG CN, YAGODA A, SCHER HI et al.: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer (1989) 64(12):2448–2458.
   Google Scholar
• HARKER WG, MEYERS FJ, FREIHA FS et al.: Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J. Clin. Oncol (1985) 3(11):1463–1470.
   PubMed Web of Science ®Google Scholar
• VON DER MAASE H, HANSEN SW, ROBERTS JT et al.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol (2000) 18(17):3068–3077.
   Google Scholar
• THRASHER J, CRAWFORD E: Current management of invasive and metastatic transitional cell carcinoma of the bladder. Urol (1993) 149(5):957–972.
   Web of Science ®Google Scholar
• FITZPATRICK JM, KHAN O, OLIVER RT, RIDDLE PR: Long-term follow-up in patients with superficial bladder tumours treated with intravesical Epodyl. Br. J. Urol. (1979) 51(6):545–548.
   PubMedGoogle Scholar
• DIVE C, HICKMAN JA: Drug-target interactions: only the first step in the commitment to a programmed cell death. Br. J. Cancer (1991) 64:192–196.
   PubMed Web of Science ®Google Scholar
• DIVE C, EVANS CA, WHETTON AD: Induction of apoptosis - new targets for cancer chemotherpy. Semin. Cancer Biol. (1992) 3:417–427.
   PubMedGoogle Scholar
• MESNER PW JR, BUDIHARDJO II, KAUFMANN SH: Chemotherapy-induced apoptosis. Adv. Pharmacol (1997) 41:461–499.
   PubMedGoogle Scholar
• KERR JF, WINTERFORD CM, HARMON BV: Apoptosis, its significance in cancer and cancer therapy. Cancer (1994) 73:2013–2026.
   PubMed Web of Science ®Google Scholar
• KELLY JD, WILLIAMSON KE, WEIR HP et al.: Induction of apoptosis by mitomycin-C in an ex vivo model of bladder cancer. BJU Int. (2000) 85(7):911–917.
   PubMed Web of Science ®Google Scholar
• HICKMAN JA: Apoptosis and chemotherapy resistance. Eur. J. Cancer (1996) 32A(6):921–926.
   PubMed Web of Science ®Google Scholar
• SEARLE J, LAWSON TA, ABBOTT PJ, HARMON B, KERR JF: An electron-microscope study of the mode of cell death induced by cancer-chemotherapeutic agents in populations of proliferating normal and neoplastic cells.j Pathol (1975) 116(3):129–138.
   PubMed Web of Science ®Google Scholar
• REED JC, DOCTOR KS, GODZIK A: The domains of apoptosis: a genomics perspective. Sci. STKE (2004) 2004(239):re9.
   Google Scholar
• ASHKENAZI A, DIXIT VM: Death receptors: signalling and modulation. Science (1998) 281(5381):1305–1308.
   PubMed Web of Science ®Google Scholar
• KING ED, MATTESON J, JACOBS SC, KYPRIANOU N: Incidence of apoptosis, cell proliferation and bc1-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J. Urol (1996) 155(1):316–320.
   PubMed Web of Science ®Google Scholar
• DUGGAN B, KELLY J, KEANE PF, WILLIAMSON K, JOHNSTON SR: Bc1-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy. BJU Int. (2000) 86(6):757.
   PubMed Web of Science ®Google Scholar
• KIRSH EJ, BAUNOCH DA, STADLER WM: Expression of bc1-2 and bcl-X in bladder cancer. J. Urol (1998) 159(4):1348–1353.
   PubMed Web of Science ®Google Scholar
• SHIINA H, IGAWA M, URAKAMI S, HONDAS, SHIRAKAWA H, ISHIBE T: Immunohistochemical analysis of bc1-2 expression in transitional cell carcinoma of the bladder./ Clin. Pathol (1996) 49(5):395–399.
   Google Scholar
• LIPPONEN PK, AALTOMAA S, ESKELINEN M: Expression of the apoptosis suppressing bc1-2 protein in transitional cell bladder tumours. Histopathology (1996) 28(2):135–140.
   PubMed Web of Science ®Google Scholar
• GLICK SH, HOWELL LP, WHITE RW: Relationship of p53 and bc1-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J. Urol (1996) 155(5):1754–1757.
   PubMed Web of Science ®Google Scholar
• DUGGAN B, KELLY J, KEANE PF, JOHNSTON SR, WILLIAMSON K: Molecular targets for the therapeutic manipulation of apoptosis in bladder cancer. J. Urol (2001) 165: 946–954.
   PubMed Web of Science ®Google Scholar
• MIYAKE H, HARA I, YAIVIANAKA K, GOHJI K, ARAKAWA S, KAMIDONO S: Overexpression of Bc1-2 enhances metastatic potential of human bladder cancer cells. Br. J. Cancer (1999) 79(11-12):1651–1656.
   PubMed Web of Science ®Google Scholar
• MIYAKE H, HANADA N, NAKAMURA H et al.: Overexpression of Bc1-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene (1998) 16(7):933–943.
   PubMed Web of Science ®Google Scholar
• ZAMECNIK P, STEPHENSON M: Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Nail. Acad. Sci. USA (1978) 75(1):280–284.
   PubMed Web of Science ®Google Scholar
• SHUTTLEWORTH J, MATTHEWS G, DALE L, BAKER C, COLMAN A: Antisense oligodeoxyribonucleotide-directed cleavage of maternal mRNA in Xenopus oocytes and embryos. Gene (1988) 72(1-2):267–275.
   PubMed Web of Science ®Google Scholar
• GILES RV RUDDELL CJ, SPILLER DG, GREEN JA, TIDD DM: Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cells. Nucleic Acids Res. (1995) 23(6):954–961.
   PubMed Web of Science ®Google Scholar
• REED J: Promise and problems of Bc1-2 antisense therapy. J. Nail Cancer Inst. (1997) 89(14):988–990.
   PubMed Web of Science ®Google Scholar
• LIMA WF, MONIA BP, ECKER DJ, FREIER SM: Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry (1992) 31(48):12055–12061.
   PubMed Web of Science ®Google Scholar
• BRANCH AD: A good antisense molecule is hard to find. Trends Biochem. Sci. (1998) 23(2):45–50.
   PubMed Web of Science ®Google Scholar
• EDER PS, DEVINE RJ, DAGLE JM, WALDER JA: Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3' exonuclease in plasma. Antisense Res. Dev. (1991) 1(2):141–151.
   PubMedGoogle Scholar
• STEIN CA: How to design an antisense oligodeoxynucleotide experiment: a consensus approach. Antisense Nucleic Acid Drug Dev. (1998) 8(2):129–132.
   PubMedGoogle Scholar
• GAUTSCHI O, TSCHOPP S, OLIE RA et al: Activity of a novel bc1-2/bc1-xL- bispecific antisense oligonucleotide against tumors of diverse histologic origins. J. NatL Cancer Inst. (2001) 93(6):463–471.
   PubMed Web of Science ®Google Scholar
• COTTER FE: Antisense therapy for lymphomas. HematoL OncoL (1997) 15(1):3–11.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S: Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides. Biochim. Biophys. Acta (1999) 1489(1):53–68.
   PubMed Web of Science ®Google Scholar
• COTTER FE, JOHNSON P, HALL P: Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene (1994) 9:3049–3055.
   PubMed Web of Science ®Google Scholar
• LOKE SL, STEIN C, ZHANG X et al.: Characterisation of oligonucleotide transport into living cells. Proc. Nail. Acad. Sci. USA (1989) 86:3474–3478.
   PubMed Web of Science ®Google Scholar
• TARI AM, TUCKERS, DEISSEROTH A, LOPEZ-BERESTEIN G: Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. Blood (1994) 84(2):601–607.
   PubMed Web of Science ®Google Scholar
• GALBRAITH WM, HOBSON WC, GICLAS PC, SCHECHTER PJ, AGRAWAL S: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev. (1994) 4(3):201–206.
   PubMedGoogle Scholar
• DUGGAN BJ, MAXWELL P, KELLY JD et al.: The effect of antisense Bc1-2 oligonucleotides on Bc1-2 protein expression and apoptosis in human bladder transitional cell carcinoma. J. UroL (2001) 166(3):1098–1105.
   PubMed Web of Science ®Google Scholar
• AGRAWAL S, TEMSAMANI J, TANG JY: Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Nail. Acad. Sci. USA (1991) 88(17):7595–7599.
   PubMed Web of Science ®Google Scholar
• IVERSEN P: In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. Anticancer Drug Des. (1991) 6(6):531–538.
   PubMedGoogle Scholar
• RAYNAUD Fl, ORR RM, GODDARD PM et aL: Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to Bc1-2, after intravenous administration or continuous subcutaneous infusion to mice. J. PharmacoL Exp. Ther. (1997) 281(1):420–427.
   PubMed Web of Science ®Google Scholar
• REED JC, CUDDY M, HALDAR S et aL: BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense. Proc. NatL Acad. Sci. USA (1990) 87(10):3660–3664.
   PubMed Web of Science ®Google Scholar
• REED JC, STEIN C, SUBASINGHE C et aL: Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. (1990) 50(20):6565–6570.
   PubMed Web of Science ®Google Scholar
• BILIM V KASAHARA T, NOBORU H, TAKAHASHI K, TOMITA Caspase involved synergistic cytotoxicity of bc1-2 antisense oligonucleotides and adriamycin on transitional cell cancer cells. Cancer Lett. (2000) 155(2):191–198.
   PubMed Web of Science ®Google Scholar
• DUGGAN BJ, COTTER FE, KELLY JD et aL: Antisense Bc1-2 oligonucleotide uptake in human transitional cell carcinoma. Eur. Urol. (2001) 40(6):685–695.
   PubMed Web of Science ®Google Scholar
• SCHAAF A, SAGI S, LANGBEIN S, TROJAN L, ALKEN P, MICHEL MS: Cytotoxicity of cisplatin in bladder cancer is significantly enhanced by application of bc1-2 antisense oligonucleotides. UroL OncoL (2004) 22(3):188–192.
   PubMed Web of Science ®Google Scholar
• LEBEDEVA I, RAFFO A, RANDO R, OJWANG J, COSSUM P, STEIN CA: Chemosensitization of bladder carcinoma cells by bc1-xL antisense oligonucleotides. UroL (2001) 166(2):461–469.
   Web of Science ®Google Scholar
• KOGA S, KONDO Y, KOMATA T, KONDO S: Treatment of bladder cancer cells in vitro and in vivo with 2-5A antisense telomerase RNA. Gene Ther. (2001) 8(8):654–658.
   PubMed Web of Science ®Google Scholar
• KRAEMER K, FUESSEL S, SCHMIDT U et aL: Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin. Cancer Res. (2003) 9(10 Pt 0:3794–3800.
   Google Scholar
• IKEMOTO S, SUGIMURA K, KURATUKURI K, NAKATANI Antitumor effects of lipoxygenase inhibitors on murine bladder cancer cell line (MBT-2). Anticancer Res. (2004) 24(2B):733–736.
   Google Scholar
• FUESSEL S, KUEPPERS B, NING S, KOTZSCH M, KRAEMER K, SCHMIDT U et aL: Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J. UroL (2004) 171(6 Pt 0:2471–2476.
   Google Scholar
• BILIM V KASAHARA T, HARA N, TAKAHASHI K, TOMITA Y: Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int. J. Cancer (2003) 103(1):29–37.
   PubMed Web of Science ®Google Scholar
• SUN HZ, WU SF, TU ZH: Blockage of IGF-1R signaling sensitizes urinary bladder cancer cells to mitomycin-mediated cytotoxicity. Cell Res. (2001) 11(2):107–115.
   PubMed Web of Science ®Google Scholar
• MIYAKE H, HARA I, KAMIDONO S, GLEAVE ME: Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity. Int. J. UroL (2001) 8(7):337–349.
   PubMed Web of Science ®Google Scholar
• LEUNG S, MIYAKE H, ZELLWEGER T, TOLCHER A, GLEAVE ME: Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bc1-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model. Int. J. Cancer (2001) 91(0:846–850.
   PubMedGoogle Scholar
• HUMPHREYS DT, CARVER JA, EASTERBROOK-SMITH SB, WILSON MR: Clusterin has chaperone-like activity similar to that of small heat shock proteins. J. Biol. Chem. (1999) 274(11):6875–6881.
   PubMed Web of Science ®Google Scholar
• KOCH-BRANDT C, MORGANS C: Clusterin: a role in cell survival in the face of apoptosis? Prog. MoL SubcelL Biol. (1996) 16:130–149.
   PubMedGoogle Scholar
• WILSON MR, EASTERBROOK-SMITH SB: Clusterin is a secreted mammalian chaperone. Trends Biochem. Sci. (2000) 25(3):95–98.
   PubMed Web of Science ®Google Scholar
• GLEAVE ME, MIYAKE H, ZELLWEGER T et al.: Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. Urology (2001) 58(2 Suppl. 0:39–49.
   Google Scholar
• MIYAKE H, HARA I, KAMIDONO S, GLEAVE ME: Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin. Cancer Res. (2001) 7(12):4245–4252.
   PubMed Web of Science ®Google Scholar
• MIYAKE H, ETO H, HARA I, SO A, LI D, GLEAVE ME: Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells. Urol. (2004) 171(6 Pt 0:2477–2481. Website
   Google Scholar
• http:www.cancerresearchuk.org/statistics Cancer Research UK, statistics.
   Google Scholar